What is it about?
The POWER Study looked at the impacts of switching from common COPD maintenance treatments (long-acting muscarinic antagonist or long-acting β2-agonist/ inhaled corticosteroids) to alternative treatment (duel bronchodilator) in patients with mild to severe COPD.
Featured Image
Photo by CDC on Unsplash
Why is it important?
COPD has a significant impact on mortality and morbidity and quality of life. While there are treatment options many leave patients still suffering from symptoms. Inhaled corticosteroids - while part of the standard treatment plans - are overprescribed and lead to long-term consequences with expended use. The POWER study found statistically significant results on CAT scores, Forced expiratory volume, and dyspnea when patients switch treatment to a duel bronchodilator.
Perspectives
Many COPD patients live with maintenance treatment that leaves them symptomatic and at increased risk of negative side effects. The POWER study echos work done in RTC trials and offers a real-life example of treatment modifications that led to improved health outcomes.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study, International Journal of Chronic Obstructive Pulmonary Disease, January 2019, Dove Medical Press, DOI: 10.2147/copd.s185485.
You can read the full text:
Resources
Contributors
The following have contributed to this page
